Tuberculin is a protein mixture that is used to diagnose tuberculosis. Purified protein derivatives are another name for these proteins. A tuberculosis skin test uses a protein generated from Mycobacterium tuberculosis to determine whether a person has been infected with the virus. The tuberculin pure protein derivative is the most widely used method for determining tuberculosis infection (PPD). The patient's skin is injected with this pure protein derivative, which is then examined for results. If the result is visible surrounding the injection site, the test is (+).
The global Tuberculin market is anticipated to increase at a 4.2 % CAGR to reach value USD 1.02 billion in 2030
Covid-19 Impact & Market Status:
A substantial number of COVID-19 cases were diagnosed and hospitalised in a short period of time during the COVID-19 outbreak, affecting other usual medical processes and medical resources. Designated hospitals that formerly operated as TB diagnostic and treatment centres have been temporarily renamed as COVID-19 diagnostic and treatment centres. Meanwhile, patients with suspected or proven tuberculosis may be hesitant to visit the hospital for fear of contracting COVID-19. This may cause diagnostic delays for suspected tuberculosis patients, negatively impacting the tuberculin industry, which is expected to rebound and develop in the coming years now that the pandemic is finished. As the pandemic is over the market start recovering and it will positively impacted the market growth of tuberculin during the period of 2022-29.
The Asia Pacific area is expected to grow at a rapid pace. The presence of growing economies like country China and India contribute to the market's growth. Both of these countries are making significant investments in healthcare infrastructure development. This has aided the growth of the tuberculin market in the region significantly. More and more significant firms in the global tuberculin market are attempting to develop operations in the region as a result of increased investments and openness in these countries. This has also aided the area market's expansion.
The PPD-S type segment is the most commonly utilised tuberculin variant because it is more widely available and has less adverse effects than the other tuberculin variants.
Due to the poorer animal healthcare infrastructure compared to human healthcare infrastructure, the human use application sector is the more dominating.
The global tuberculin market is predicted to be worth around USD 876.3 million by the end of 2029, with a CAGR of around 5.28 percent between 2022 and 2029.
The overall development of the worldwide tuberculin market is influenced by a number of variables. The rising prevalence of tuberculosis around the world, notably in the Asia Pacific region, is one of the primary factors driving the worldwide tuberculin market forward. Furthermore, rising awareness of health problems is assisting in the growth of the worldwide tuberculin market.
Another important element driving the global tuberculin market's expansion is the expanding research and development efforts. The global tuberculin market is predicted to reach new s in the following years of the forecast period, thanks to rising finances and investments from both the private and public sectors. Furthermore, various government-sponsored health-awareness initiatives around the world are assisting in the expansion of the worldwide tuberculin market.
Aside from the benefits of tuberculin, there are setback to be aware of. The tuberculin market is being held back by anaphylactic and foreign body reactions, which cause swelling, itching, and other allergic reactions.
The major market players of Tuberculin Market are Zoetis, Sanroad Biological, Japan BCG, Sanofi Pasteur, SSI, Thermo Fisher, Par Sterile and CNBG, among others.
Major Developments in Tuberculin Market:
Thermo Fisher Scientific, a global leader in tuberculin research and development, said in October 2019 that it has successfully taken over an API production plant from GlaxoSmithKline, another pharma behemoth. The deal is worth roughly 90 million euros in total. Around 400 employees of the GSK Manufacturing Site in Cork, Ireland, will now be a part of Thermo Fisher Scientific Inc.'s pharma division, according to the new agreement.
Another prominent brand in the global tuberculin industry, Zoetis, revealed in August 2019 that it had successfully purchased Platinum Performance. Zoetis' product range is likely to be bolstered as a result of this acquisition.
Tuberculin Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2028||USD 876.3 million|
|Growth Rate||CAGR of 5.28 % during 2021-2028|
|Segment Covered||Type, Application, Regions|
|Regions Covered||North America, Europe, Asia Pacific, Middle East and Africa, South America|
|Key Players Profiled||Zoetis, Sanroad Biological, Japan BCG, Sanofi Pasteur, SSI, Thermo Fisher, Par Sterile and CNBG, among others.|
Key Segments of Tuberculin Market
- By Type
- PPD RT23
- By Application
- Human Use
- Animal Use
- By Region
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa